Stocksigma LogoStocksigma Logo

Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue

Chandra Bhagat Pharma Limited received in-principle approval from BSE on 12th Oct'26 for a preferential issue under Regulation 28(1) of SEBI LODR

Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue

Chandra Bhagat Pharma Ltd 路 Others (Uncategorized) 路 13 Oct 2026, 6:01 pm

Chandra Bhagat Pharma Receives In-Principle Approval for Preferential Issue Chandra Bhagat Pharma Limited received in-principle approval from BSE on 12th Oct'26 for a preferential issue under Regulation 28(1) of SEBI LODR Regulations. The approval covers 66,00,000 warrants convertible into 66,00,000 equity shares of face value Rs. 10 each. The securities will be issued to promoter and non-promoter groups at a floor price of Rs. 44 per share, subject to post-issue formalities, statutory compliances, and listing applications within twenty days from allotment.

Original exchange filing (PDF)

More announcements from Chandra Bhagat Pharma Ltd

All Chandra Bhagat Pharma Ltd announcements